Le Lézard
Classified in: Health
Subject: FDA

Pollogen's Leading Home-Use Device, TriPollar Stop, Receives FDA Clearance


TEL AVIV, Israel, Aug. 14, 2019 /PRNewswire/ -- FDA has cleared Pollogen's RF home-use device ? TriPollar Stop ? for sale in the US. TriPollar Stop, the innovative home-use device developed by Pollogen, is based on the company's clinically-proven, patented RF technology, and has enjoyed broad market acceptance outside the US over the last few years.

Pollogen's leading Home-Use Device, TriPollar Stop, Receives FDA Clearance (PRNewsfoto/Pollogen Ltd)

"TriPollar Stop has been our flagship product for the home market," says Sharon Ravid, CEO of Pollogen, "and we are very excited about the opportunity to offer this device to home users in the US."

The TriPollar Stop device is indicated for the treatment of the face and the neck, eliminating aging signs, reducing lines and wrinkles and improving skin strength, texture and elasticity. By implementing Pollogen's innovation of triple-axis RF waves, the device introduces heat to the dermis, which induces regeneration of the basic building blocks of the skin ? collagen and elastin fibers. Results are visible immediately after the treatment and can be maintained via a cycle of repeated treatments.

TriPollar Stop is part of the TriPollar product line developed by Pollogen for home users. This exclusive product line is based on Pollogen's innovative technologies, all tried and tested by clinicians in the professional aesthetic device market. The ingenuity of the TriPollar line lies in the company's ability to take these technologies and present them to the users in a handy, comfortable device without compromising on the safety and the quality of results.

The TriPollar home-use devices, are created with the company's innovative development concept of Intelligent Biology ? achieving the desired aesthetic results by encouraging the natural processes of the body for renewal and rejuvenation. "We believe that home users today are not only concerned with the beauty per se but also seek health and ethics," explains Ravid. "All the TriPollar products work in sync under the umbrella of Intelligent Biology to achieve skin health and improvement in the most natural way our body can offer."

About Pollogen

Pollogen Ltd., a company of Lumenis, is a global leader in the medical and home-based aesthetics markets, providing innovative, safe, and effective solutions that enhance and expand the practice of medical aesthetics professionals, as well as private aesthetic customers. The company offers products to support a range of skin treatments, based on its proprietary technologies, namely Tripollar RF, Voluderm, Trifractional, Oxygeneo and DMA. Pollogen provides solutions for professionals and consumers in more than 60 countries, addressing the specific needs of its professional clients and private customers in the dynamic aesthetic industry. For more information visit: www.pollogen.com

About Lumenis 

Lumenis is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology, and Aesthetic, Surgical, and Ophthalmology markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For 50 years, Lumenis' ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods. Lumenis is a portfolio company of XIO Group, a global alternative investments firm headquartered in London. For more information visit: www.lumenis.com

Contact information:
Michele Michaeli
michele_m@pollogen.com

 

SOURCE Pollogen Ltd


These press releases may also interest you

at 03:05
Merck, a leading science and technology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion to update the product label of Rebif®, an interferon...

at 03:01
AbbVie , a research-based global biopharmaceutical company, today announced experts in the neuroscience field will present results from two late-breaking abstracts, including final data from the Phase 1b study evaluating the safety and tolerability...

at 03:00
Biogen Inc.  today announced that the Committee for Medicinal Products for Human Use (CHMP), part of the of the European...

at 03:00
Promising results from the preclinical study conducted by Menarini Ricerche on MEN1611, a potent and selective orally available phosphatidylinositol 3-kinase (PI3K) inhibitor currently in development for the treatment of breast cancer. The poster...

at 03:00
TAMPA, Fla., Sept. 23, 2019  3Lions Publishing, Inc. (3LP), the owner/operator of the HIPAA Survival Guide, is pleased to announce Release 2.5 of Expresso® featuring our Breach Notification Wizard. Expresso® 2.5 is available for purchase on the HIPAA...

at 03:00
Children want to meet adult expectations, misbehaving only if they can't help it for one or two reasons (assuming they don't have health or nutrition or serious family difficulty): 1. A child's ability to function normally requires basic...



News published on 14 august 2019 at 09:47 and distributed by: